Genprex Hosts Investor Webinar with Andreea Porcelli 2nd April

Published by

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR
on the timeline of Swiss Growth Forum

Mar 31, 2020

Genprex Hosts Investor Webinar with Andreea Porcelli 2nd April

Thank you to everyone who participated in our recent events in Europe. In this time of crisis, the Swiss Growth Forum offers our best wishes that you remain well and safe during the current COVID-19 pandemic. Given our collective need to practice social distancing and shelter in place in many states and nations, we are replacing our in-person Forums and Roadshows, launching a new IR/PR service in conjunction with SmartMoneyMatch.com, a global platform for financial and investment professionals and IRTH Communications, effective investor relations, social media, and public relations. This new service will include Webinars and One-to-One calls with Company CEOs.

Rodney Varner, CEO of Genprex, whom you may have been introduced to during our Winter Forum events, is eager to follow-up with any and all investors who would like more information or did not get a chance to meet with him last month. He will be hosting a Webinar with Andreea Porcelli, CEO of Swiss Growth Forum, next Thursday, 2nd April at 17:00 CET to discuss Genprex’s latest developments and answer any questions you may have. Please RSVP and find the dial-in details HERE. If you are unable to participate in this Webinar, but would still like to speak with Mr. Rodney Varner, we would be happy to coordinate a One-to-One call at your convenience.

In case you missed Genprex’s latest news releases, please find them HERE.

Get the Webinar Details Here


About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with serious diseases that currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develops drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases. The Company’s lead product candidate, Oncoprex™, is being evaluated as a treatment for non-small cell lung cancer (NSCLC).  Oncoprex has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for Oncoprex immunogene therapy for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®). For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on TwitterFacebook, and LinkedIn.
 
 
 
 
Questions? Contact christine@swissgrowthforum.io
About Swiss Growth Forum by Andreea Porcelli
Swiss Growth Forum (SGF) is an exclusive, invitation-only conference highlighting growth companies seeking capital and/or greater exposure. Andreea Porcelli, SGF founder, and CEO has more than 20 years’ experience as an international investment banker, finding investors for small-cap companies on a global scale. She and her team select, by-invitation-only, companies seeking international investor exposure to present and then socialize over three days with institutional fund managers, private asset managers, high-net-worth individuals, and industry-related sponsors and foundations—all of whom are also exclusively invited to match SGF’s highly selective criteria.

Articles authored by Martin Signer

Published: May 17, 2020

Published: May 12, 2020

Published: May 11, 2020

Published: May 6, 2020

Published: Apr 27, 2020

Published: Apr 26, 2020

Published: Apr 15, 2020

Published: Apr 6, 2020

Published: Mar 24, 2020

Published: Mar 18, 2020

Published: Mar 18, 2020

Published: Mar 18, 2020

Published: Mar 9, 2020

Published: Mar 6, 2020

Published: Mar 4, 2020

Published: Mar 2, 2020

Published: Feb 24, 2020

Published: Feb 18, 2020

Published: Feb 11, 2020

Published: Feb 9, 2020

Published: Jan 17, 2020

Published: Jan 7, 2020

Published: Jan 3, 2020

Published: Dec 25, 2019

Published: Dec 18, 2019

Published: Nov 26, 2019

Published: Nov 6, 2019

Published: Oct 20, 2019

Published: Oct 12, 2019

Published: Oct 11, 2019

Published: Oct 3, 2019

Published: Oct 2, 2019

Published: Oct 1, 2019

Published: Sep 29, 2019

Published: Sep 29, 2019

Published: Sep 19, 2019

Published: Sep 16, 2019

Published: Sep 14, 2019

Published: Sep 5, 2019

Published: Sep 3, 2019

Published: Aug 30, 2019

Published: Aug 29, 2019

Published: Aug 15, 2019

Published: Jul 21, 2019

Published: Jul 8, 2019

Published: Jun 29, 2019

Published: Jun 11, 2019

Published: May 22, 2019

Published: May 5, 2019

Published: Apr 21, 2019

Published: Apr 19, 2019

Published: Mar 28, 2019

Published: Mar 16, 2019

Published: Mar 16, 2019

Published: Mar 6, 2019

Published: Feb 25, 2019

Published: Feb 24, 2019

Published: Feb 7, 2019

Published: Apr 20, 2018

Published: Feb 18, 2018

Published: Feb 7, 2018